Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 9/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5250320 | 1.00 | PDE5A (0.80) | PDE5A | |
| SCHEMBL1679631 | 0.91 | PDE5A (0.82) | PDE5A | |
| SCHEMBL1679628 | 0.91 | PDE5A (0.82) | PDE5A | |
| SCHEMBL8499754 | 0.90 | PDE5A (0.89) | PDE5A | |
| SCHEMBL28412519 | 0.90 | PDE5A (0.83) | PDE5A | |
| SCHEMBL8486537 | 0.90 | PDE5A (0.83) | PDE5A | |
| SCHEMBL5246869 | 0.89 | PDE5A (0.79) | PDE5A | |
| SCHEMBL5246859 | 0.89 | PDE5A (0.79) | PDE5A | |
| SCHEMBL8507921 | 0.89 | PDE5A (0.80) | PDE5A | |
| SCHEMBL8487823 | 0.89 | PDE5A (0.81) | PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1219609-B1 | AROMATIC NITROGENOUS SIX-MEMBERED RING COMPOUNDS | TANABE SEIYAKU CO (JP) | 2007-04-04 | — | — | EP | disclosed |
| US-6797709-B2 | SEXUAL DISORDERS | TANABE SEIYAKU CO., LTD. (JP) | 2004-09-28 | — | — | US | disclosed |
| US-20030229095-A1 | Sexual disorders | TANABE SEIYAKU CO., LTD. | 2003-12-11 | — | — | US | disclosed |
| US-6656935-B2 | Treatment of penile erectile dysfunction, pulmonary hypertension, and diabetic gastroparesis | TANABE SEIYAKU CO., LTD. (JP) | 2003-12-02 | — | — | US | disclosed |
| US-20030032647-A1 | Treatment of penile erectile dysfunction, pulmonary hypertension, and diabetic gastroparesis | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2003-02-13 | — | — | US | disclosed |
| CN-1374953-A | 6-membered aromatic ring compound containing nitrogen | TANABE SEIYAKU CO (JP) | 2002-10-16 | — | — | CN | disclosed |
| EP-1219609-A1 | AROMATIC NITROGENOUS SIX-MEMBERED RING COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2002-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032647-A1 | Treatment of penile erectile dysfunction, pulmonary hypertension, and diabetic gastroparesis | PDE3A, PDE3B, PDE2A | PDE5A 4/4885 |
| US-20030229095-A1 | Sexual disorders | PDE3B, PDE3A, PDE2A | PDE5A 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.